AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Lysophosphatidic acid receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q92633

UPID:

LPAR1_HUMAN

Alternative names:

Lysophosphatidic acid receptor Edg-2

Alternative UPACC:

Q92633; B4DK36; O00656; O00722; P78351

Background:

Lysophosphatidic acid receptor 1 (LPA1), also known as Edg-2, is a crucial receptor for lysophosphatidic acid (LPA). It plays a pivotal role in actin cytoskeleton reorganization, cell migration, differentiation, and proliferation. LPA1 activation triggers multiple signaling pathways, including G(i)/G(o), G(12)/G(13), and G(q) families, leading to various cellular responses such as decreased cAMP levels, increased cytoplasmic Ca(2+) levels, and activation of MAP kinases. It is essential for normal brain development, skeleton development, and the regulation of cell shape.

Therapeutic significance:

Understanding the role of Lysophosphatidic acid receptor 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.